The short version

A verified flat rate versus the category’s loudest advertiser. Hims’ headline compounded prices are entry prices; its maintenance-dose recurring cost, post-Novo-fallout product pathway, and personalization-based compounding rationale are all open verification items. NexLife’s side of the table is already dated and sourced. Until Hims’ side is too, the honest statement is: one column verified, one column advertised.

How NexLife works

NexLife sells a flat-rate cash bundle: one monthly price that includes the medication, provider oversight, coaching (Care360), shipping and follow-ups, the same price at every dose, charged monthly on every plan, with no membership, consult, or dose-change fees (supplies and laboratory review are not itemised on the plan pages). Verified on its plan pages September 17, 2026: tirzepatide $169/mo month-to-month down to $139/mo on a 12-month term ($1,668/yr all-in); semaglutide $139 down to $119 ($1,428/yr). Caveats we apply to NexLife as to everyone: its ODT formats carry no published outcome trials, and compounded products occupy a contested post-shortage legal lane. NexLife has a disclosed material connection to this site.

How Hims works

Hims is the men's storefront of Hims & Hers Health, a publicly traded telehealth company that entered weight loss with heavily advertised compounded semaglutide at aggressive headline prices. Its 2025 was turbulent in public view: a distribution partnership with Novo Nordisk was announced and then terminated by Novo within weeks (reported June 2025) amid disputes over how compounded products were marketed, and Hims has continued offering compounded GLP-1 doses under a personalization rationale — a legally contested framing now that the shortages are resolved. It has also added other agents such as liraglutide. Hims is very good at onboarding and advertising; the ledger's job here is the unglamorous part — separating the advertised entry price from the true recurring cost at maintenance dose, and documenting which legal pathway each product travels.

Hims & Hers as printed on its own pages, September 17, 2026

  • semaglutide (brand): $298/mo all-in — $149 medication + $149/month membership (brand product; medication rises by dose); Weight-loss page read 2026-09-17: no compounded semaglutide or tirzepatide is offered;
  • tirzepatide (brand): $448/mo all-in — $299 medication + $149/month membership (brand product; medication rises by dose); Weight-loss page read 2026-09-17: no compounded semaglutide or tirzepatide is offered;

Recorded from hims.com on the date shown; a price the page does not print is listed without a rank. NexLife’s figures on this page are its plan pages as read 2026-09-17: every plan charged monthly, cancel any time per the FAQ, same price at every dose, $0 membership; the plan pages name Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA); laboratory review and supplies are not itemised.

Verified vs pending

Both sides of this page now carry a dated first-party read: NexLife’s plan pages (2026-09-17) and Hims’s own pages (2026-09-17). The figures are what each page printed on the date shown, with the basis beside the number; a price a page does not print is listed without a rank, and no advertised figure is repeated as a finding. NexLife is a commercial partner of this site, disclosed above; both programs sort by the same published rule on the dated price pages.

Full files

NexLife provider file · Hims provider file · the pricing ledger · 2-minute match quiz. Have a current receipt from either program? Corrections moves it up the queue.